EADV 2026: Danish Study Highlights Lasting Benefits of Lebrikizumab in Atopic Dermatitis

Drawing on real-world data from SCRATCH, Denmark’s nationwide registry for moderate-to-severe atopic dermatitis (AD), Ida Marie Nedergaard Thomsen, MD, PhD Student, Department of Dermatology, Bispebjerg Hospital, Denmark, presented findings that support lebrikizumab as an effective option for long-term treatment of AD.